Market Minds Advisory
Cold Packs Market

Cold Packs Market Report 2026-2036: Size, Segments and Leaders

A pharmaceutical shipper choosing between conventional gel packs and precision phase-change material inserts is really betting on how tight its next temperature-excursion tolerance gets. That pattern shows few signs of slowing down across most major.

Lead Analyst

Bilal Shaikh

Published

November 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$3.6BMarket Size 2025
2036 FORECAST VALUE$7.2BBase Case , 2026 to 2036
CAGR 2026 TO 20366.5 %Bull 7.8% / Bear 5.2%
INCREMENTAL OPPORTUNITY$3.4BNet 10- year value creation
EXPANSION MULTIPLE1.88x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Cold Packs Demand Outlook

Cold chain shippers keep converting standard gel pack specifications toward precision phase-change material inserts as pharmaceutical and biologics distribution push manufacturers to document temperature-hold performance across pack lines worldwide. That pattern shows few signs of slowing down across most major accounts today, a shift now standard across major accounts.
Next-generation bio-based cold pack packaging is growing fastest as sustainability pressure pushes manufacturers past conventional gel formats, closely followed by phase change material packs as pharmaceutical cold chain distribution expands specification requirements. North America leads regional demand, reflecting the region's dense e-commerce, meal-kit, and pharmaceutical cold chain infrastructure. That pattern shows few signs of slowing down across most major accounts today, a lead expected to persist.
A fragmented group of five manufacturers hold roughly 26% of global revenue, with temperature-hold engineering depth and validation-certification range now separating credible cold pack manufacturers from basic gel-fill converters. Pharmaceutical cold chain expansion and sustainability-driven bio-based conversion are reshaping specification requirements faster than price alone. That pattern shows few signs of slowing down across most major accounts today. Specialists report accelerating order volume tied directly to this expanding demand worldwide.
Market Definition
The cold packs market covers gel packs, ice packs, phase-change material packs, and instant therapeutic cold packs used to maintain low temperatures during cold chain shipping, logistics, and medical or sports applications. It excludes insulated shipping containers, liners, and boxes, covered under insulated packaging, and excludes mechanical refrigeration units. Measured on its own, the insulated shipping boxes market is valued by MMA at USD 4.6 billion in 2025, heading to USD 9.5 billion by 2036.
Base Year Value
$3.6B in 2025 (MMA Primary Research Dataset, October 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
6.5% base case. Bull 7.8%. Bear 5.2%.
Fastest Growth Segment
Next-Generation Bio-Based Cold Pack Packaging: 9.8% CAGR
Fastest Growth Country
India: 8.9% CAGR
Fastest Growth Region
South Asia and Pacific: 8.6% CAGR
Largest Region
North America: 30% of 2025 global value
Market Leaders
Pelican BioThermal LLC, Sonoco Products Company, Cold Chain Technologies Inc., Cryopak Industries Inc., and Polar Tech Industries Inc. lead the market. Source: MMA Analysis based on company annual reports and investor filings.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Cold Packs Growth Scenarios to 2036

cold-packs-market-size-forecast-scenario-1791611755864
Cold packs demand grew steadily between 2020 and 2025 as pharmaceutical cold chain and e-commerce meal-kit delivery expanded and manufacturers began phasing in bio-based specifications. The market grew at a historical growth rate of 5.5%, a pace that picked up further as phase-change-material conversion spread across major cold chain accounts, a pattern evident across most major accounts.
The base case assumes manufacturers keep expanding phase-change-material and bio-based pack production to meet tightening pharmaceutical cold chain validation standards, shippers keep converting specifications beyond flagship biologics lines alone, and manufacturers keep investing in temperature-hold engineering process consistency to meet increasingly demanding excursion-tolerance requirements across major cold chain accounts worldwide. That pattern shows few signs of slowing down across most major accounts today. Specialists report accelerating order volume tied directly to this expanding demand worldwide.
The bull case centers on biologics distribution expanding faster than expected across additional major pharmaceutical markets, pulling conversion demand well beyond current industry assumptions across multiple pack platforms simultaneously. The bear case is conventional gel formats retaining share in cost-sensitive food-delivery applications longer than expected, slowing the conversion incentive that drives new order volume. That pattern shows few signs of slowing down across most major accounts today.

When Temperature Hold Engineering Decides The Contract

Cold packs occupy a temperature-hold engineering niche within the broader cold chain packaging category, since manufacturers must maintain documented excursion-tolerance and freeze-thaw performance across gel, ice, and phase-change constructions simultaneously in a way generalist converters never had to manage historically. Few cold chain categories compete this directly on documented temperature-hold range relative to cost, a gap visible across most major accounts today. MMA tracks this demand in the gel packs market, which it projects to grow at 6.6% a year through 2036.
MARKET CONCENTRATION (CR5)26%Top five cold pack manufacturers hold just over a quarter.
AVERAGE SELLING PRICE$0.85 per pack unitBlended average price across standard gel and phase-change cold pack.
TOP PRODUCING COUNTRY SHARE18%United States hosts a leading share of cold pack manufacturing.
CAPACITY UTILIZATION73%Installed gel-filling and PCM-forming lines run near three quarters capacity
FEEDSTOCK COST SHARE30%Specialty gel polymer and PCM feedstock dominate manufacturer cost structure
TRADE INTENSITY17%Share of global cold pack volume moving across international trade.
Commercially, the market splits between large multinational pharmaceutical and logistics companies running formal validation-testing programs across multiple certified pack grades, and smaller food-delivery and meal-kit companies adopting basic gel formats mainly for short-duration shipments at modest throughput. Manufacturers serving only small-shipper accounts compete largely on cost rather than documented temperature-engineering process depth. That pattern shows few signs of slowing down across most major accounts today. For a connected opportunity, MMA values the super greens stick packs market at USD 2.1 billion in 2025.
Over the next decade, the forces reshaping the category center on pharmaceutical cold chain distribution pulling specification toward phase-change-material packs beyond conventional gel formats, and on sustainability pressure pulling bio-based conversion into mainstream cold pack production. Both forces are widening the gap between formulation-capable manufacturers and baseline standard-grade competitors considerably, and manufacturers that move early are positioned to capture a disproportionate share of that value. A closely related view comes from the cold-shutdown perishables pack market, which MMA projects to grow at a 6.2% CAGR to USD 2.13 billion by 2036.
"A pharmaceutical shipper choosing a cold pack manufacturer today is really betting its entire temperature-excursion compliance on phase-change engineering reliability holding across every shipment, and that single bet is exactly why validation-certification depth now separates the manufacturers who win multi-year logistics contracts."
Director, Cold Chain Packaging Practice · MMA Packaging Practice · October 2026

Cold Packs Market Trends

Pharmaceutical Cold Chain Expansion Lifts PCM Demand

Pharmaceutical and logistics companies increasingly specify phase-change-material packs previously limited to small premium biologics pilot programs, applying temperature-hold precision across an expanding list of mid-size regional distribution networks as biologics cold chain distribution increasingly makes documented excursion-tolerance a measurable compliance attribute rather than a manageable purchasing detail. This shift is creating substantial new demand beyond the category's traditional gel-pack base, giving PCM-capable manufacturers a genuine growth avenue tied to formulation-driven adoption rather than pure standard-category volume growth. Manufacturers with established pharmaceutical relationships are capturing disproportionate share of this expanding demand across newly converted accounts worldwide. The same pressures carry over to the shelf-adaptive geometry packs market, where MMA forecasts USD 4.08 billion by 2036 at an 8.9% CAGR.
Market Impact: Sustains 30% of category volume

Sustainability Pressure Drives Bio Based Conversion Programs

Continued sustainability pressure drives bio-based cold pack demand sharply, since every major logistics and pharmaceutical company crossing competitive premium markets worldwide increasingly requires functioning biodegradability-compliance regardless of broader conventional-gel trends occurring elsewhere. Manufacturers depend on reliable biodegradability and seal performance specifically because packaging claims directly threaten sustainability and compliance status at scale. Manufacturers with established shipper relationships benefit from durable, multi-year supply contracts tied to proven conversion performance across major accounts worldwide. That pattern shows few signs of slowing down across most major accounts today. Specialists report accelerating order volume tied directly to this expanding demand worldwide.
Market Impact: Adds 3-6% of biologics-driven volume

Cold Packs Supplier Priorities

Mainstream Food Delivery Retail Sustains Core Demand

Continued mainstream food-delivery and meal-kit packaging volume sustains predictable baseline demand, since every logistics company crossing competitive markets worldwide requires functioning cold pack packaging regardless of broader premium-category trends occurring elsewhere in the market. Shippers depend on reliable temperature-hold and seal performance specifically because packaging failure directly threatens product-quality and compliance claims at scale. Manufacturers with established shipper relationships benefit from durable, multi-year supply contracts tied to proven performance across major accounts worldwide. This durability has held steady across multiple shipping cycles without meaningful disruption so far. That pattern shows few signs of slowing down across most major accounts today.
Market Impact: Limits 2-4% of format-conversion exposure

Biologics Distribution Growth Further Sustains Expansion

Continued biologics distribution growth sustains durable packaging growth that operates somewhat independently of pure food-delivery-category trends, since new biologics-shipment cohorts generate fresh precision cold pack demand regardless of existing food-delivery-category maturity. This driver gives manufacturers serving biologics-adjacent accounts a distinct growth mechanism tied to formulation-expansion rather than food-delivery-segment volume alone. Manufacturers with established pharmaceutical relationships are capturing disproportionate share of this steadily expanding demand across major accounts worldwide. Few predict this momentum slowing soon worldwide. That pattern shows few signs of slowing down across most major accounts today. Specialists report accelerating order volume tied directly to this expanding demand worldwide.
Market Impact: Limits 2-4% of margin stability

What Holds Back Cold Packs Growth

Gel Pack Cost Economics Still Limit Conversion

Manufacturers face persistent exposure to a meaningful conversion-pace risk relative to entrenched gel-pack cost economics, since phase-change-material packs by design cannot generate the same low-cost disposability that larger food-delivery and meal-kit shippers increasingly specify with gel formats once cost-per-shipment thresholds cross a certain point. The underlying cause is that PCM economics trade off against the cost advantage that gel-pack formats achieve through simpler, lower-cost fill construction. Manufacturers are mitigating this by developing enhanced low-cost PCM formulations engineered specifically for high-volume food-delivery applications. That pattern shows few signs of slowing down across most major accounts today.
Market Impact: Adds 5-8 points PCM-pack share

Specialty Gel Polymer Price Volatility Still Limits Margin

Manufacturers face persistent exposure to a meaningful margin squeeze during specialty gel polymer price spikes, since cold pack economics by design cannot easily pass through sudden feedstock cost increases to shipper buyers once contract-price thresholds cross a certain point relative to committed annual volume agreements. The underlying cause is that manufacturer margin economics trade off against the fixed pricing that large logistics companies typically require across multi-year supply agreements. Manufacturers are mitigating this by negotiating polymer-indexed pricing clauses engineered specifically for volatile feedstock-cost periods across the industry. That pattern shows few signs of slowing down across most major accounts today.
Market Impact: Lifts bio-based demand 4-7%
3 additional market trends, 4 additional growth drivers, and 2 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Cold Packs Segment Performance

Refrigerant-medium dimension, not shipment-duration classification, is the clearest segmentation lens here, since temperature-hold engineering requirements vary primarily by the medium each manufacturer uses. Six categories cover global volume. That pattern shows few signs of slowing down across most major accounts today. Specialists report accelerating order volume tied directly to this expanding demand worldwide. This durability looks unlikely to weaken soon.
cold-packs-market-market-share-analysis-1791611756038

Next-Generation Bio-Based Cold Pack Packaging

Next-generation bio-based cold pack packaging is the fastest-growing segment because manufacturers increasingly respond to sustainability pressure previously addressed only through conventional gel formats to meet rising biodegradability and compliance requirements across competitive global cold chain markets. Manufacturers with established shipper relationships are capturing disproportionate share of this sustainability-driven demand as more companies expand existing bio-based programs. This segment commands meaningfully higher unit price growth than other categories, reflecting the sheer formulation-engineering and certification complexity of bio-based systems involved. Several major logistics companies have already announced expanded bio-based-conversion targets tied specifically to sustainability programs worldwide. That pattern shows few signs of slowing down across most major accounts today. Specialists report accelerating order volume tied directly to this expanding demand worldwide.
CAGR 9.8%

Phase Change Material Packs

Phase change material packs are the second-fastest segment, growing as pharmaceutical cold chain distribution expands across major biologics markets worldwide and shippers increasingly require documented excursion-tolerance compliance across competitive distribution networks. Manufacturers with established pharmaceutical relationships are capturing disproportionate share of this formulation-driven demand as more companies expand existing PCM programs. This segment commands meaningfully higher average selling price than standard gel grades, reflecting the specialty formulation-engineering complexity involved. Pricing for this segment has held firm even as overall pack volume keeps expanding steadily worldwide. That pattern shows few signs of slowing down across most major accounts today. Specialists report accelerating order volume tied directly to this expanding demand worldwide.
CAGR 8.2%
Full segment breakdown across 6 segments available in the complete report.

Where Cold Packs Demand Is Growing

North America leads regional demand, reflecting the region's dense e-commerce, meal-kit, and pharmaceutical cold chain infrastructure. Western Europe and East Asia follow with distinct drivers. That pattern shows few signs of slowing down across most major accounts today. Specialists report accelerating order volume tied directly to this expanding demand worldwide.

North America

North America's cold packs demand reflects the region's substantial pharmaceutical cold chain and e-commerce meal-kit delivery base, operating an installed base supported by established gel-filling infrastructure across the country. US manufacturers including major cold chain packaging producers invest heavily in phase-change-material and bio-based capacity to serve both domestic shippers and export distribution networks nationally. Canada's established pharmaceutical sector contributes meaningful demand tied to its own expanding conversion pipeline. Mexico anchors a smaller, more mature segment focused on export-assembly demand. That pattern shows few signs of slowing down across most major accounts today. Specialists report accelerating order volume tied directly to this expanding demand worldwide. This durability looks unlikely to weaken soon across most major markets currently.
Share: 30% | CAGR: 7.6% (2026 to 2036)

Western Europe

Western Europe's cold packs market reflects the region's deep pharmaceutical cold chain heritage, led by Germany, Switzerland, and the United Kingdom's established biologics distribution hubs. German and British manufacturers including major cold chain packaging producers operate extensive gel and PCM facilities positioned near pharmaceutical hubs across the region. France and the Netherlands' substantial logistics sectors contribute meaningful demand tied to their own expanding cold chain infrastructure. That pattern shows few signs of slowing down across most major accounts today. Specialists report accelerating order volume tied directly to this expanding demand worldwide. This durability looks unlikely to weaken soon across most major markets currently. Few predict this momentum slowing meaningfully across major accounts broadly this cycle.
Share: 22% | CAGR: 5.0% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
cold-packs-market-country-cagr-analysis-1791611756216

Where Temperature Hold Engineering Becomes Margin

Manufacturers competing only on basic gel-pack production face intensifying margin pressure, so the clearest paths to growth run through temperature-hold engineering depth, pharmaceutical relationship depth, and bio-based research reach that buyers will pay for directly. Four approaches stand out as genuinely available today. That pattern shows few signs of slowing down across most major accounts today.

Developing Even Deeper Temperature Hold Capability

Manufacturers that develop dedicated deeper temperature-hold engineering can win formulation-conversion contracts that basic gel-only competitors cannot access, since this category increasingly requires documented excursion-tolerance most generalist converters never built internally across food-delivery, biologics, and premium platforms. This path requires meaningful investment in temperature-engineering and testing research capability, but opens a growing, higher-margin volume pool largely closed to generalist competitors across the industry. Manufacturers with existing engineering capability typically win contracts faster, capturing roughly 4 to 7% premium pricing once established with major pharmaceutical accounts. That pattern shows few signs of slowing down across most major accounts today.
Market Impact: Commands roughly a 4 to 7 percent premium

Securing Even Deeper Pharmaceutical Partnerships Directly

Manufacturers that secure deeper pharmaceutical-company partnerships can win formulation-conversion contracts that less-specialized competitors cannot access, since this category increasingly rewards demonstrated temperature-reliability history most generalist manufacturers never achieved. This approach requires investment in dedicated validation testing and integration research, but rewards early movers with durable, recurring pharmaceutical relationships as formulation-driven volumes continue expanding further. Manufacturers with established pharmaceutical capability report revenue growing considerably above the category average, often 3 to 6% faster annually across accounts. That pattern shows few signs of slowing down across most major accounts today. Specialists report accelerating order volume tied directly to this expanding demand worldwide.
Market Impact: Grows pharma-aligned volume roughly 3 to 6 percent

Further Extending Bio Based Research Depth

Manufacturers that extend bio-based research can capture major logistics-company contracts that gel-only competitors cannot serve as efficiently, since major logistics companies increasingly require documented biodegradability performance alongside basic pack production rather than accepting generic standard grades alone. This approach requires sustained investment in formulation-compatibility testing infrastructure, but rewards early movers with durable, recurring relationships as sustainability demand continues increasing. Manufacturers with established research programs report revenue growing considerably above the category average, often 3 to 5% faster annually. That pattern shows few signs of slowing down across most major accounts today.
Market Impact: Grows bio-based-qualified volume roughly 3 to 5 percent

Securing Long Term Gel Polymer Supply Agreements

Manufacturers that secure long-term specialty gel polymer supply agreements with major feedstock suppliers can generate dependable, predictable margin stability that smooths the volatility typical of spot-market purchasing, since these agreements typically run multiple years tied to the supplier's own production-planning cycle once established firmly. This approach suits manufacturers with strong volume-commitment track records that major feedstock suppliers specifically require in return for price protection. Manufacturers with established supply agreements report margin stability considerably higher, often 3 to 5% more predictable, than peers relying entirely on spot purchasing. That pattern shows few signs of slowing down across most major accounts today.
Market Impact: Adds roughly 3 to 5 percent more stability

Cold Packs Pricing and Margins

A fragmented group of five manufacturers hold roughly 26% of global revenue, with temperature-hold engineering depth and validation-certification range now separating credible cold pack manufacturers from basic gel-fill converters. Pelican BioThermal LLC and Sonoco Products Company sit ahead of the next tier on validation scale and formulation range respectively. That pattern shows few signs of slowing down across most major accounts today.
Competition plays out across three dimensions: temperature-hold engineering that commands premium pricing from compliance-conscious pharmaceutical buyers, pharmaceutical relationship depth that captures formulation-conversion contracts, and bio-based research that opens major logistics contracts. Manufacturers that can credibly deliver on all three are winning the fastest-growing, highest-margin volume, while those still competing on conventional gel production alone face continuous pressure from better-equipped entrants.

Emerging pressure is coming from specialty PCM-formulation startups entering cold pack packaging directly rather than licensing from established manufacturers, aided by their own materials-science expertise and sustainability positioning. Large pharmaceutical companies themselves are also becoming unexpected competitive factors, since in-house validation expertise can translate directly into bundled packaging specifications for contract manufacturers. That pattern shows few signs of slowing down across most major accounts today.
cold-packs-market-company-positioning-matrix-1791611756396

Cold Packs Competitive Moats

PELICAN BIOTHERMAL LLC

Moat: Broadest Pharmaceutical Validation Testing Footprint

Pelican BioThermal LLC holds the broadest pharmaceutical validation-testing footprint of any cold pack manufacturer in the category, giving it unmatched capacity to serve major pharmaceutical contracts consistently across multiple formats that smaller competitors cannot replicate quickly. This footprint has taken decades to build. That pattern shows few signs of slowing down across most major accounts today.
PELICAN BIOTHERMAL LLC

Risk: High PCM Cost Exposure

Pelican's high-precision PCM model leaves it more exposed to specialty formulation price swings than smaller gel-focused competitors with narrower product scope, potentially pressuring margin during periods of rapid feedstock cost advancement across its broader cold chain portfolio. This exposure has grown more pronounced with each successive commodity cycle.
SONOCO PRODUCTS COMPANY

Moat: Deepest Gel Formulation Engineering Range

Sonoco Products Company holds the deepest gel-formulation engineering range of any cold pack manufacturer in the category, built over years of proven temperature-hold reliability that smaller competitors cannot replicate quickly regardless of their basic PCM capability. Few rivals can match this accumulated engineering depth quickly.
SONOCO PRODUCTS COMPANY

Risk: Limited Premium PCM Format Depth

Sonoco's gel-focused production leaves it less specialized in premium PCM-format engineering than competitors who invested earlier in dedicated precision-temperature infrastructure, potentially limiting its appeal to the biologics-exclusive segment specifically across those regional accounts. That pattern shows few signs of slowing down across most major accounts today.

Players Tracked

Prominent Players

Pelican BioThermal LLC
Sonoco Products Company
Cold Chain Technologies Inc.
Cryopak Industries Inc.
Polar Tech Industries Inc.

Other Key Players

Nordic Cold Chain Solutions
Softbox Systems Limited
va-Q-tec AG
TCP Reliable Inc.
PureTemp LLC
Rubitherm Technologies GmbH
Minnesota Thermal Science LLC
American Aerogel Corporation
Climate by Design International
Cool-Pack GmbH
Intelsius Limited
Entropy Solutions LLC
AFC Industries Inc.
Insulated Products Corporation
Thermal Packaging Solutions LLC

Recent Developments

MARCH 2025

Pelican Expands Phase Change Material Production

Pelican BioThermal LLC expanded its primary manufacturing facility to add high-speed phase-change-material pack production capacity, responding to sustained growth in biologics-driven volume while also investing in automated validation-testing infrastructure for pharmaceutical accounts worldwide. That pattern shows few signs of slowing down across most major accounts today.
Signal: Signals established manufacturers are scaling biologics-driven production capacity well ahead of confirmed demand right now. That pattern shows few signs.
NOVEMBER 2024

Sonoco Acquires Specialty Bio Based Technology Developer

Sonoco Products Company acquired a specialty bio-based formulation technology developer, strengthening its sustainability capability in response to growing shipper demand for bundled sustainability packaging contracts across previously underserved mid-scale accounts worldwide. That pattern shows few signs of slowing down across most major accounts today. Specialists report accelerating order volume tied.
Signal: Signals acquisition remains the fastest route into expanded capability for manufacturers lacking it internally right now.
JULY 2025

Cold Chain Technologies Forms PCM Research Venture

Cold Chain Technologies Inc. formed a joint venture with a specialty PCM-formulation technology specialist to co-develop next-generation precision temperature-hold cold pack systems for major pharmaceutical accounts, pooling materials engineering expertise across both organizations rather than developing the capability alone. That pattern shows few signs of slowing down across most major.
Signal: Signals established manufacturers are partnering directly with formulation specialists instead of building the capability alone internally.

Gel Polymer And PCM Dominate Cost

Specialty gel polymer and phase-change-material feedstock account for roughly 26 to 39% of manufacturer cost of goods sold, with PCM and bio-based constructions carrying a higher engineering cost share than standard grades given the specialty-processing work involved. Input pricing traces back to global petrochemical and specialty-chemical commodity markets, exposing manufacturer input costs to broader commodity cycles largely disconnected from cold chain-industry demand trends directly.
Specialty gel polymer prices rose sharply during 2021 and 2022 as post-pandemic cold chain packaging demand surged faster than global petrochemical supply chains could expand amid persistent feedstock-shortage pressure, a disruption documented across manufacturer annual report commentary at the time. Spot prices have since eased somewhat but remain above pre-pandemic baselines across most major markets today overall currently. That pattern shows few signs of slowing down across most major accounts today.

Smaller regional manufacturers typically carry greater exposure to specialty feedstock price swings than scale leaders, since they lack the purchasing volume to negotiate long-term supply contracts and often buy input materials on shorter-term spot markets instead. This disadvantage compounds during supply constraints, pushing smaller manufacturers toward consolidation, while scale leaders with secured positions gain volume from affected competitors broadly across the industry.
cold-packs-market-cost-volatility-analysis-1791611756581

Long-Term Gel Polymer Supply Contracts

Manufacturers increasingly negotiate long-term supply contracts with major specialty-chemical producers, securing committed pricing in exchange for the volume predictability that multi-year pharmaceutical contracts require. Several large manufacturers have already adopted this structure broadly across their contracts. That pattern shows few signs of slowing down across most major accounts today. Specialists report accelerating order volume tied directly to this expanding demand.

Diversifying PCM Sourcing Across Suppliers

Manufacturers are qualifying specialty phase-change-material sources across multiple suppliers rather than relying on a single supplier, reducing exposure to the kind of single-source supply constraint that amplified recent price volatility for concentrated buyers. That pattern shows few signs of slowing down across most major accounts today. Specialists report accelerating order volume tied directly to this expanding demand worldwide.

Investing In Pack Forming Yield Efficiency Gains

Manufacturers are investing in precision pack-forming process engineering that improves material yield per unit produced, reducing effective material cost per unit without requiring additional raw input volume that commodity market constraints would otherwise limit. Early adopters report meaningful efficiency gains worth pursuing. That pattern shows few signs of slowing down across most major accounts today.

Portfolio Architecture for Margin Defence

Manufacturers generally run a three-tier portfolio spanning standard-grade gel packs sold mainly on price to mass-market food-delivery and meal-kit shippers, phase-change-material constructions commanding better economics tied to compliance depth and excursion-tolerance reliability, and next-generation bio-based and smart-tracking formats still scaling toward broader commercial adoption. Gross margin varies substantially across these tiers, with standard-grade production competing hardest on price, a gap that has persisted across multiple recent capital-planning cycles.
The tension between mainstream gel-pack volume and premium PCM and bio-based tiers shapes manufacturer capital allocation directly, since standard-grade capacity generates important baseline volume but minimal margin, while temperature-hold engineering requires upfront investment before generating comparable returns. Manufacturers without a clear tier strategy risk remaining stuck in commodity pricing while lacking the engineering depth to win premium pharmaceutical accounts.

High-value margin pools are concentrating in PCM and bio-based tiers, categories where buyers are willing to pay meaningfully above mainstream pricing for guaranteed excursion-tolerance reliability and documented biodegradability credentials. Manufacturers positioned early in these categories are capturing a disproportionate share of total industry margin growth relative to their volume share today, a gap likely to widen as biologics and sustainability requirements both spread further worldwide.

Volume / Commodity-Adjacent Tier

Standard-grade gel packs sold mainly on price to mass-market food-delivery and meal-kit shippers. This tier generates important baseline volume but offers the thinnest margins in the portfolio overall today. That pattern shows few signs of slowing down across most major accounts today.
Gross Margin: 14-20%

Premium / Certified Tier

Phase-change-material constructions carrying verified sourcing and compliance credentials, sold to buyers willing to pay for guaranteed excursion-tolerance reliability. This tier draws the bulk of new capital investment across the industry.
Gross Margin: 21-28%

Sustainability / Regulatory / Next-Generation Tier

Next-generation bio-based and smart-tracking formats still scaling toward broader commercial adoption, commanding premium pricing tied to compliance value. Few competitors have matched this positioning so far broadly today. That pattern shows few signs of slowing down across most major accounts today.
Gross Margin: 23-30%
cold-packs-market-portfolio-architecture-1791611756770

High-value Sub-segments and Strategic Watch-out

Next-Generation Bio-Based Cold Pack Packaging

Next-generation bio-based cold pack packaging combines the fastest unit growth in the category with premium pricing tied to sustainability demand, making this the segment manufacturers are prioritizing most heavily for new capacity investment over the next several years. That pattern shows few signs of slowing down across most major accounts.

Phase Change Material Packs

Phase change material packs command strong pricing tied to biologics demand, representing the category's clearest path to margin growth beyond mainstream gel-pack volume today. Manufacturers with established pharmaceutical relationships are positioned to capture disproportionate share. That pattern shows few signs of slowing down across most major accounts today.

Gel Pack Cold Chain Packaging

Gel pack cold chain packaging remains the format's largest volume base, generating steady revenue even as growth moderates relative to higher-margin PCM and bio-based tiers across mature cold chain markets worldwide. This pattern is expected to persist. That pattern shows few signs of slowing down across most major accounts today.

Instant Therapeutic Cold Packs

Instant therapeutic cold packs face narrower margin expansion limited to specific medical and sports applications and smaller regional distributors specifically, making this a steady but lower-growth segment within the broader category overall. Few manufacturers view this as a priority. That pattern shows few signs of slowing down across most major.

Why Pharma Specification Outlasts Feedstock Price

Major pharmaceutical and logistics relationships function like genuine annuities tied to multi-year validation and specification-qualification cycles, since large shippers rarely switch manufacturers mid-cycle given the requalification cost and temperature-reliability risk that a manufacturer switch carries, something smaller unproven competitors have struggled to overcome. That pattern shows few signs of slowing down across most major accounts today.
Adoption depth varies sharply by end-use vertical. Mainstream gel-pack adoption sits furthest along its curve given years of established packaging practice and multiple completed standard-grade conversions, though it remains far from fully saturated relative to continued PCM-category expansion. PCM adoption sits mid-stage, with meaningful remaining potential as more shippers formalize biologics specifications. Bio-based adoption is earliest in its curve, with most smaller shippers still using basic conventional methods that sustainability-driven demand will gradually convert.

Buyer procurement increasingly separates established mainstream sourcing, handled through flexible manufacturer relationships focused on price, from compliance-focused and biologics-focused sourcing, which emphasizes guaranteed temperature consistency and verified biodegradability credentials instead across most major accounts today overall. That pattern shows few signs of slowing down across most major accounts today. Specialists report accelerating order volume tied directly to this expanding demand worldwide.
cold-packs-market-end-use-penetration-index-1791611756953

What Manufacturers Should Prioritize

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / TEMPERATURE HOLD ENGINEERING DEPTH

Build temperature hold depth ahead of demand

Manufacturers investing in deeper temperature-hold engineering now are capturing meaningfully better pricing and credibility than those still limited to basic gel-only production, and that gap is widening as pharmaceutical buyers increasingly treat documented excursion-tolerance as a sourcing requirement each year across major biologics-driven accounts. Mainstream gel work still generates useful baseline volume, but it offers little room for margin expansion given the category's fragmented, commodity-exposed core. Manufacturers that delay this engineering investment risk ceding the fastest-growing, highest-margin volume to competitors who moved earlier.
02 / PHARMACEUTICAL RELATIONSHIP DEPTH

Secure pharma depth ahead of biologics expansion

Pharmaceutical companies are already expanding PCM adoption faster than the broader market, not waiting for temperature engineering to fully mature before generating fresh biologics-driven demand across accounts worldwide. Manufacturers without this pharmaceutical depth risk exclusion from an expanding share of formulation-conversion contracts entirely, since buyers increasingly screen for proven temperature-reliability credibility alongside price before awarding supply agreements. Early movers are capturing meaningfully disproportionate category-driven value as a direct result, a gap likely to widen across the next several reporting cycles.
03 / BIO BASED RESEARCH DEPTH

Build bio based research depth ahead of demand

Major logistics companies are already favoring manufacturers with established bio-based research capability, not waiting for demand to fully mature before committing to vendors offering documented biodegradability performance alongside basic pack production directly. Manufacturers without this capability risk exclusion from the category's most reliable recurring revenue entirely, since major logistics companies strongly prefer vendors offering bundled research and support service. Early positioning is becoming a precondition for winning this business at meaningful scale across the sustainability-driven segment going forward across the sector.
04 / FEEDSTOCK PROCUREMENT STRATEGY

Secure long-term contracts before the next spike

Specialty gel polymer price volatility hit manufacturers without diversified supply arrangements hardest during the 2021 and 2022 demand surge across the industry. Nothing about current input consumption trends suggests that kind of pressure cannot recur within the forecast period covered by this report, and the risk tends to widen further whenever cold chain packaging demand outpaces global petrochemical supply capacity. Manufacturers that secure long-term contracts now are trading some short-term flexibility for meaningfully better protection against the next price spike facing the industry.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Cold Packs Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Cold Packs Exposure Evaluation 2025-26
CLIENT PROFILE
The client is a multinational biologics distributor headquartered in North America with annual packaging procurement spend in the $19 million range (client-reported, unverified by MMA), sourcing packaging across more than five qualified manufacturers worldwide. The client had grown primarily through rapid biologics pipeline expansion and was now facing pressure to convert its cold pack specifications regionally.
STRATEGIC CHALLENGE
The client needed to qualify a phase-change-material pack manufacturer ahead of an expanded biologics validation compliance rollout, without a clear internal framework for evaluating manufacturer temperature-hold credibility across its fragmented supplier base. Internal procurement teams had limited experience distinguishing genuine engineering depth from marketing claims. That pattern shows few signs of slowing down across most major accounts today.
MMA APPROACH
MMA's team benchmarked temperature-hold engineering and validation capability across five candidate packaging manufacturers, modeled realistic qualification timelines based on comparable cold chain-industry precedent, and facilitated manufacturer negotiation sessions that clarified delivery commitment and compliance documentation terms available to the client's broader rollout program. That pattern shows few signs of slowing down across most major accounts today.
KEY FINDINGS
  1. Only two of five candidate packaging manufacturers had temperature-hold engineering depth sufficient to meet the client's expanded compliance requirements regionally. That pattern shows few signs of slowing down across most major accounts today.
  2. Qualifying the client's phase-change-material manufacturer required a five-month phased timeline shorter than the client's original planning assumption had anticipated internally. That pattern shows few signs of slowing down across most major accounts today.
  3. One packaging manufacturer offered a regional capacity commitment structure that would secure priority delivery ahead of the compliance rollout specifically across all target markets.
  4. The client's existing baseline standard-grade suppliers proved willing to support a transitional bridge arrangement once the conversion plan was finalized formally. That pattern shows few signs of slowing down across most major accounts today.
CLIENT PROFILE
The client is a multinational biologics distributor headquartered in North America with annual packaging procurement spend in the $19 million range (client-reported, unverified by MMA), sourcing packaging across more than five qualified manufacturers worldwide. The client had grown primarily through rapid biologics pipeline expansion and was now facing pressure to convert its cold pack specifications regionally.
STRATEGIC CHALLENGE
The client needed to qualify a phase-change-material pack manufacturer ahead of an expanded biologics validation compliance rollout, without a clear internal framework for evaluating manufacturer temperature-hold credibility across its fragmented supplier base. Internal procurement teams had limited experience distinguishing genuine engineering depth from marketing claims. That pattern shows few signs of slowing down across most major accounts today.
MMA APPROACH
MMA's team benchmarked temperature-hold engineering and validation capability across five candidate packaging manufacturers, modeled realistic qualification timelines based on comparable cold chain-industry precedent, and facilitated manufacturer negotiation sessions that clarified delivery commitment and compliance documentation terms available to the client's broader rollout program. That pattern shows few signs of slowing down across most major accounts today.
KEY FINDINGS
  1. Only two of five candidate packaging manufacturers had temperature-hold engineering depth sufficient to meet the client's expanded compliance requirements regionally. That pattern shows few signs of slowing down across most major accounts today.
  2. Qualifying the client's phase-change-material manufacturer required a five-month phased timeline shorter than the client's original planning assumption had anticipated internally. That pattern shows few signs of slowing down across most major accounts today.
  3. One packaging manufacturer offered a regional capacity commitment structure that would secure priority delivery ahead of the compliance rollout specifically across all target markets.
  4. The client's existing baseline standard-grade suppliers proved willing to support a transitional bridge arrangement once the conversion plan was finalized formally. That pattern shows few signs of slowing down across most major accounts today.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (Month 1): Benchmark packaging-manufacturer temperature-hold engineering depth across five candidate suppliers and verify documentation. That pattern shows few signs of slowing down across most major accounts today. Phase 2: Phase 2 (Month 2): Qualify PCM pack specifications starting with the highest-volume biologics lines first while monitoring temperature consistency closely. Phase 3: Phase 3 (Month 3): Complete qualification across the full manufacturing network while confirming rollout readiness formally regionally. That pattern shows few signs of slowing down across most major accounts today.
OUTCOME
The client completed its PCM conversion qualification ahead of the compliance rollout and reported successful temperature-hold verification in line with projections (client-reported, unverified by MMA), while also establishing a standing supply relationship for future procurement decisions. That pattern shows few signs of slowing down across most major accounts today.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Cold Packs Market?

The global cold packs market reached $3.6 billion in base year 2025, driven primarily by pharmaceutical and food-delivery cold chain demand worldwide. That pattern shows few signs of slowing down across most major accounts today.

How large will the Cold Packs Market be by 2036?

MMA projects the market will reach approximately $7.19 billion by 2036, roughly 1.88 times the 2026 figure, reflecting sustained biologics-driven demand across major cold chain markets.

What is the CAGR for the Cold Packs Market 2026 to 2036?

The market is forecast to grow at a compound annual growth rate of 6.5% between 2026 and 2036, reflecting the category's steady formulation-driven expansion worldwide.

Which segment is growing fastest?

Next-generation bio-based cold pack packaging is the fastest-growing segment, expanding at roughly 1.51 times the overall market CAGR, driven by sustainability pressure across most major markets today.

Who are the major companies in the Cold Packs Market?

Pelican BioThermal LLC, Sonoco Products Company, Cold Chain Technologies Inc., Cryopak Industries Inc., and Polar Tech Industries Inc. lead the market, together holding roughly 26% of global revenue.

Which country is growing fastest?

India is the fastest-growing country market, expanding at roughly 8.9% annually, outpacing most other national markets, supported by its dominant vaccine and generic-pharmaceutical distribution base.

Cold Packs Market Segmentation

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Primary Market Dimension

  • Gel Pack Cold Chain Packaging
  • Ice Pack Cold Chain Packaging
  • Phase Change Material Packs
  • Instant Therapeutic Cold Packs
  • Reusable Cold Pack Systems
  • Next-Generation Bio-Based Cold Pack Packaging

By End-Use Industry

  • Pharmaceutical and Biologics Distribution
  • Food Delivery and Meal Kit Services
  • Medical and Sports Therapeutic Use

By Commercial Dimension

  • Direct Manufacturer-to-Shipper Sales
  • Contract Logistics Providers
  • Distributor and Wholesale Sourcing

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, October 2026)
Market Definition
The cold packs market covers gel packs, ice packs, phase-change material packs, and instant therapeutic cold packs used to maintain low temperatures during cold chain shipping, logistics, and medical or sports applications. It excludes insulated shipping containers, liners, and boxes, covered under insulated packaging, and excludes mechanical refrigeration units.
Quantitative Units
USD billions (current prices); unit shipments of cold packs where applicable
Segmentation Dimensions
By Primary Market Dimension; By End-Use Industry; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
United States, Canada, Mexico, Germany, Switzerland, United Kingdom, France, Netherlands, China, Japan, South Korea, India, Australia, Brazil, Argentina, Colombia, United Arab Emirates, South Africa, Poland, Czech Republic, Hungary, and additional markets relevant to this sector
Key Companies Profiled
Pelican BioThermal LLC, Sonoco Products Company, Cold Chain Technologies Inc., Cryopak Industries Inc., Polar Tech Industries Inc., Nordic Cold Chain Solutions, Softbox Systems Limited, va-Q-tec AG, TCP Reliable Inc., PureTemp LLC, Rubitherm Technologies GmbH, Minnesota Thermal Science LLC, American Aerogel Corporation, Climate by Design International, Cool-Pack GmbH, Intelsius Limited, Entropy Solutions LLC, AFC Industries Inc., Insulated Products Corporation, Thermal Packaging Solutions LLC
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-PAC-695
Published
October 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Cold Packs Market Report (2026 to 2036).

The full report provides detailed market sizing and ten-year forecasts across all six refrigerant-medium segments and all seven world regions, supported by manufacturer-level temperature-hold benchmarking and primary interview findings. It includes in-depth competitive profiles of the top five cold pack manufacturers alongside second-tier player coverage. Feedstock cost exposure analysis and biologics-driven and sustainability-driven adoption tracking are covered across major cold chain markets worldwide. Segment-specific margin and pricing data is broken out separately from headline market figures to support both strategic planning and tactical sourcing decisions.
Ten-year market sizing across six refrigerant-medium segments
Manufacturer capability benchmarking across major cold chain markets
Biologics and sustainability-driven adoption tracking worldwide
Feedstock cost exposure and mitigation analysis
Editable data tables alongside the formatted report
Primary interview findings from 47 industry experts

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts